Table 1

Patient characteristics in groups with and without MR toxicity

VariableTotal (n = 148)No toxicity (n = 115)Toxicity* (n = 33)P
No.%No.%No.%
Mean age at diagnosis, y (± SD) 60 ± 13 61 ± 13 57 ± 15 .19 
Male sex 69 47 56 49 13 39 .43 
Diagnosis       .09 
 Follicular lymphoma 122 82 95 82 27 82 
 Mantle cell lymphoma 14 10 18 
 Marginal zone lymphoma  
 Lymphoplasmacytic lymphoma  
Ann Arbor stage       .40 
 Limited (I-II) 21 14 15 13 18 
 Advanced (III-IV) 127 86 100 87 27 82 
B symptoms 19 13 17 15 .25 
Extranodal involvement 96 65 73 63 23 70 .54 
Transformed 21 14 17 15 12 1.00 
Induction regimen       .046 
 R-CHOP/R-CVP 83 56 70 61 13 39 
 BR 65 44 45 39 20 61 
No. of induction cycles       .13 
 4 
 5 
 6 135 91 107 93 28 85 
Response to induction       .21 
 Complete response 102 69 76 67 26 79 
 Partial response/stable disease 45 31 38 33 21 
Maintenance schedule       .002 
 Every 2 mo 41 28 24 21 17 52 
 Every 3 mo 107 72 91 79 16 49 
VariableTotal (n = 148)No toxicity (n = 115)Toxicity* (n = 33)P
No.%No.%No.%
Mean age at diagnosis, y (± SD) 60 ± 13 61 ± 13 57 ± 15 .19 
Male sex 69 47 56 49 13 39 .43 
Diagnosis       .09 
 Follicular lymphoma 122 82 95 82 27 82 
 Mantle cell lymphoma 14 10 18 
 Marginal zone lymphoma  
 Lymphoplasmacytic lymphoma  
Ann Arbor stage       .40 
 Limited (I-II) 21 14 15 13 18 
 Advanced (III-IV) 127 86 100 87 27 82 
B symptoms 19 13 17 15 .25 
Extranodal involvement 96 65 73 63 23 70 .54 
Transformed 21 14 17 15 12 1.00 
Induction regimen       .046 
 R-CHOP/R-CVP 83 56 70 61 13 39 
 BR 65 44 45 39 20 61 
No. of induction cycles       .13 
 4 
 5 
 6 135 91 107 93 28 85 
Response to induction       .21 
 Complete response 102 69 76 67 26 79 
 Partial response/stable disease 45 31 38 33 21 
Maintenance schedule       .002 
 Every 2 mo 41 28 24 21 17 52 
 Every 3 mo 107 72 91 79 16 49 

Proportions were compared by using the χ2 method (and Fisher’s exact test) and continuous variables were compared by using the Student t test.

SD, standard deviation.

*

Any grade toxicity (see supplemental Table 1).

or Create an Account

Close Modal
Close Modal